Golec, Joseph; Vernon, John - In: PharmacoEconomics 26 (2008) 12, pp. 1005-1017
Government policy debates on pharmaceutical pricing often turn on whether higher drug prices fund greater company-financed R&D spending. In the US, debate breaks down because each side uses a different measure of R&D spending, and the measures are far apart. Government agencies, Congress and...